NASDAQ:CV CapsoVision (CV) Stock Price, News & Analysis $6.59 -0.03 (-0.45%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$6.49 -0.10 (-1.52%) As of 10/9/2026 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About CapsoVision Stock (NASDAQ:CV) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CapsoVision alerts:Sign Up Key Stats Today's Range$6.54▼$6.7350-Day Range$5.82▼$7.1752-Week Range$4.38▼$15.37Volume57,969 shsAverage Volume283,235 shsMarket Capitalization$329.83 millionP/E RatioN/ADividend YieldN/APrice Target$9.50Consensus RatingHold Company Overview CapsoVision, Inc. is a medical technology company focused on developing and commercializing capsule endoscopy systems for gastrointestinal imaging. Its technology is designed to allow physicians to examine the digestive tract using an ingestible capsule that contains miniature cameras, eliminating the need for a conventional endoscope to reach certain areas of the small intestine. The company’s principal product is the CapsoCam Plus capsule endoscopy system, which uses panoramic imaging to capture views of the small intestine as the capsule passes naturally through the gastrointestinal tract. CapsoVision also provides related software and image-review tools intended to help healthcare professionals collect, process and evaluate capsule endoscopy images. CapsoVision serves the gastrointestinal diagnostics market, including hospitals, specialty clinics and physicians who evaluate conditions such as gastrointestinal bleeding, inflammatory bowel disease and other disorders affecting the small intestine. The company is headquartered in the United States and has sought to expand the use of its capsule-based imaging technology through regulatory clearances and commercialization in multiple markets.AI Generated. May Contain Errors. Read More CapsoVision Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreCV MarketRank™: CapsoVision scored higher than 66% of companies evaluated by MarketBeat, and ranked 337th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingHold Consensus RatingCapsoVision has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialCapsoVision has a consensus price target of $9.50, representing about 44.2% upside from its current price of $6.59.Amount of Analyst CoverageCapsoVision has only been the subject of 4 research reports in the past 90 days.Read more about CapsoVision's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for CapsoVision are expected to grow in the coming year, from ($0.56) to ($0.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CapsoVision is -14.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CapsoVision is -14.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCapsoVision has a P/B Ratio of 23.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.30% of the float of CapsoVision has been sold short.Short Interest Ratio / Days to CoverCapsoVision has a short interest ratio ("days to cover") of 5.44.Change versus previous monthShort interest in CapsoVision has recently increased by 10.81%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCapsoVision does not currently pay a dividend.Dividend GrowthCapsoVision does not have a long track record of dividend growth. News and Social Media1.7 / 5News Sentiment-0.36 News SentimentCapsoVision has a news sentiment score of -0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for CapsoVision this week, compared to 2 articles on an average week.Search Interest1 people have searched for CV on MarketBeat in the last 30 days. Company Ownership3.7 / 5Insider TradingAcquiring Shares Cluster Insider Buying2 insiders have purchased shares of CapsoVision in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $15,410,983.00 in company stock, which represents 4.6724% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, CapsoVision insiders have bought more of their company's stock than they have sold. Specifically, they have bought $15,410,983.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders2.30% of the stock of CapsoVision is held by insiders.Percentage Held by InstitutionsCapsoVision has minimal institutional ownership at this time.Read more about CapsoVision's insider trading history. Receive CV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CapsoVision and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CV Stock News HeadlinesCapsoVision (NASDAQ:CV) versus Anteris Technologies Global (NASDAQ:AVR) Financial ComparisonOctober 6, 2026 | americanbankingnews.comBrainsway (NASDAQ:BWAY) and CapsoVision (NASDAQ:CV) Critical ReviewOctober 5, 2026 | americanbankingnews.comFirst Look: Elon’s “Starphone”Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to be thinner, longer-lasting on battery, and cheaper to produce, with the ability to work worldwide without relying on cell towers. Former Bloomberg reporter and SAC Capital trader Josh Baylin says the evidence is mounting. He notes the FCC recently gave Musk a green light connected to his mobile plans, adding fuel to speculation. Baylin previously called the smartphone boom in 2004 and predicted Apple would sell a billion phones when others expected a fraction of that. | Stansberry Research (Ad)CapsoVision gets FDA clearance for AI HighlightsSeptember 30, 2026 | americanbankingnews.comCapsoVision Announces FDA Clearance of AI Highlights for CapsoCam Plus(R)September 29, 2026 | marketscreener.comMCapsoVision Gets FDA Clearance for AI-Assisted Capsule Endoscopy ToolSeptember 28, 2026 | marketscreener.comMEliyahou Et Al Harari Purchases 1,757,469 Shares of CapsoVision (NASDAQ:CV) StockSeptember 24, 2026 | insidertrades.comInsider Buying: CapsoVision (NASDAQ:CV) Major Shareholder Buys $4,999,996.46 in StockSeptember 19, 2026 | insidertrades.comSee More Headlines CV Stock Analysis - Frequently Asked Questions How have CV shares performed this year? CapsoVision's stock was trading at $10.69 at the beginning of 2026. Since then, CV shares have decreased by 38.4% and is now trading at $6.59. How were CapsoVision's earnings last quarter? CapsoVision, Inc. (NASDAQ:CV) announced its earnings results on Thursday, August, 13th. The company reported ($0.15) EPS for the quarter. The business had revenue of $3.64 million for the quarter. CapsoVision had a negative net margin of 214.74% and a negative trailing twelve-month return on equity of 177.85%. Read the conference call transcript. When did CapsoVision IPO? CapsoVision (CV) raised $28 million in an IPO on Wednesday, July 2nd 2025. The company issued 5,300,000 shares at a price of $5.00-$5.50 per share. The Benchmark Company and Roth Capital Partners acted as the underwriters for the IPO. How do I buy shares of CapsoVision? Shares of CV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/13/2026Today10/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 CV's financial health is in the Green zone, according to TradeSmith. CV has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:CV CIK1378325 Webcapsovision.com Phone(408) 370-4790FaxN/AEmployees99Year Founded2005Price Target and Rating Average Price Target for CapsoVision$9.50 High Price Target$10.00 Low Price Target$9.00 Potential Upside/Downside+44.2%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$25.32 million Net Margins-214.74% Pretax Margin-214.56% Return on Equity-177.85% Return on Assets-135.07% Debt Debt-to-Equity RatioN/A Current Ratio3.35 Quick Ratio2.44 Sales & Book Value Annual Sales$13.55 million Price / Sales24.34 Cash FlowN/A Price / Cash FlowN/A Book Value$0.28 per share Price / Book23.54Miscellaneous Outstanding Shares50,050,000Free Float48,896,000Market Cap$329.83 million OptionableN/A Beta-2.45 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:CV) was last updated on 10/10/2026 by MarketBeat.com Staff. From Our PartnersIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA simple options setup that cuts through the noiseIan Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, an...TradeWins | SponsoredTech expert smashes iPhone with golf clubTwenty years ago, Josh Baylin told Congress the iPhone was coming, three years before it launched. A $1,500 be...Stansberry Research | SponsoredElon’s Hiding a Potential $20 Trillion Monster Inside TeslaElon Musk says there is a product inside Tesla's factories he calls the biggest ever made, ten times bigger th...StocksToTrade | SponsoredOil Surge Predicted…Oil markets are heating up heading into 2026, and Marc Lichtenfeld, Chief Income Strategist at The Oxford Club...The Oxford Club | SponsoredBanking NightmareDuring the 2008 financial crisis, 485 US banks failed. Martin D. Weiss called 484 of them, a 99.8% accuracy ra...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CapsoVision, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CapsoVision With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
